Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
6.51
-0.21 (-3.12%)
At close: Dec 5, 2025, 4:00 PM EST
6.64
+0.13 (2.00%)
After-hours: Dec 5, 2025, 7:17 PM EST
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Xeris Biopharma Holdings stock have an average target of 10, with a low estimate of 6.00 and a high estimate of 18. The average target predicts an increase of 53.61% from the current stock price of 6.51.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xeris Biopharma Holdings stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $18 | Buy | Maintains | $18 | +176.50% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +53.61% | Nov 7, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $6 → $8 | Hold | Maintains | $6 → $8 | +22.89% | Nov 7, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $8 → $18 | Buy | Maintains | $8 → $18 | +176.50% | Oct 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +53.61% | Sep 17, 2025 |
Financial Forecast
Revenue This Year
293.17M
from 203.07M
Increased by 44.37%
Revenue Next Year
374.87M
from 293.17M
Increased by 27.87%
EPS This Year
-0.03
from -0.37
EPS Next Year
0.16
from -0.03
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 303.0M | 453.9M | ||||
| Avg | 293.2M | 374.9M | ||||
| Low | 279.3M | 331.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 49.2% | 54.8% | ||||
| Avg | 44.4% | 27.9% | ||||
| Low | 37.5% | 13.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.01 | 0.43 | |
| Avg | -0.03 | 0.16 | |
| Low | -0.05 | -0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.